PMID- 18634981
OWN - NLM
STAT- MEDLINE
DCOM- 20080904
LR  - 20151119
IS  - 1558-3597 (Electronic)
IS  - 0735-1097 (Linking)
VI  - 52
IP  - 4
DP  - 2008 Jul 22
TI  - Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type 
      natriuretic peptide in patients with chronic heart failure: prediction of death 
      at different stages of the disease.
PG  - 266-72
LID - 10.1016/j.jacc.2008.03.050 [doi]
AB  - OBJECTIVES: This study sought to evaluate the predictive value of copeptin over 
      the entire spectrum of heart failure (HF) and compare it to the current benchmark 
      markers, B-type natriuretic peptide (BNP) and N-terminal pro-B-type natriuretic 
      peptide (NT-proBNP). BACKGROUND: Vasopressin has been shown to increase with the 
      severity of chronic HF. Copeptin is a fragment of pre-pro-vasopressin that is 
      synthesized and secreted in equimolar amounts to vasopressin. Both hormones have 
      a short lifetime in vivo, similar to BNPs, but in contrast to vasopressin, 
      copeptin is very stable in vitro. The predictive value of copeptin has been shown 
      in advanced HF, where it was superior to BNP for predicting 24-month mortality. 
      METHODS: This was a long-term observational study in 786 HF patients from the 
      whole spectrum of heart failure (New York Heart Association [NYHA] functional 
      class I to IV, BNP 688 +/- 948 pg/ml [range 3 to 8,536 pg/ml], left ventricular 
      ejection fraction 25 +/- 10% [range 5% to 65%]). RESULTS: The NYHA functional 
      class was the most potent single predictor of 24-month outcome in a stepwise Cox 
      regression model. The BNP, copeptin, and glomerular filtration rate were related 
      to NYHA functional class (p < 0.0001 for trend). Copeptin was the most potent 
      single predictor of mortality in patients with NYHA functional class II (p < 
      0.0001) and class III (p < 0.0001). In NYHA functional class IV, the outcome of 
      patients was best predicted by serum sodium, but again, copeptin added additional 
      independent information. CONCLUSIONS: Increased levels of copeptin are linked to 
      excess mortality, and this link is maintained irrespective of the clinical signs 
      of severity of the disease. Copeptin was superior to BNP or NT-proBNP in this 
      study, but the markers seem to be closely related.
FAU - Neuhold, Stephanie
AU  - Neuhold S
AD  - Department of Cardiology, Medical University of Vienna, Vienna, Austria.
FAU - Huelsmann, Martin
AU  - Huelsmann M
FAU - Strunk, Guido
AU  - Strunk G
FAU - Stoiser, Brigitte
AU  - Stoiser B
FAU - Struck, Joachim
AU  - Struck J
FAU - Morgenthaler, Nils G
AU  - Morgenthaler NG
FAU - Bergmann, Andreas
AU  - Bergmann A
FAU - Moertl, Deddo
AU  - Moertl D
FAU - Berger, Rudolf
AU  - Berger R
FAU - Pacher, Richard
AU  - Pacher R
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - United States
TA  - J Am Coll Cardiol
JT  - Journal of the American College of Cardiology
JID - 8301365
RN  - 0 (Biomarkers)
RN  - 0 (Glycopeptides)
RN  - 0 (Peptide Fragments)
RN  - 0 (copeptins)
RN  - 0 (pro-brain natriuretic peptide (1-76))
RN  - 11000-17-2 (Vasopressins)
RN  - 114471-18-0 (Natriuretic Peptide, Brain)
SB  - IM
MH  - Austria/epidemiology
MH  - Biomarkers/blood
MH  - Disease Progression
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Glycopeptides/*blood
MH  - Heart Failure/*blood/*mortality/physiopathology
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Natriuretic Peptide, Brain/*blood
MH  - Peptide Fragments/blood
MH  - Predictive Value of Tests
MH  - Prognosis
MH  - Proportional Hazards Models
MH  - ROC Curve
MH  - Severity of Illness Index
MH  - Stroke Volume
MH  - Time Factors
MH  - Vasopressins/metabolism
EDAT- 2008/07/19 09:00
MHDA- 2008/09/05 09:00
CRDT- 2008/07/19 09:00
PHST- 2007/12/20 00:00 [received]
PHST- 2008/03/10 00:00 [revised]
PHST- 2008/03/18 00:00 [accepted]
PHST- 2008/07/19 09:00 [pubmed]
PHST- 2008/09/05 09:00 [medline]
PHST- 2008/07/19 09:00 [entrez]
AID - S0735-1097(08)01590-8 [pii]
AID - 10.1016/j.jacc.2008.03.050 [doi]
PST - ppublish
SO  - J Am Coll Cardiol. 2008 Jul 22;52(4):266-72. doi: 10.1016/j.jacc.2008.03.050.